PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) — SEC Filings

Latest SEC filings for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB), explained in plain English.

Sentiment Overview: 1 bullish, 2 bearish, 41 neutral

Recent Filings (44)

• PacBio's Q3 Loss Widens Amid Soaring Intangible Asset Amortization — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported a significant net loss of $506.005 million for the nine months ended September 30, 2025, a substantial i
• 8-K Filing — 8-K · 2025-11-05T00:00:00.000Z [neutral]
• PacBio's Q2 Revenue Jumps 33% on Strong Product Sales — 10-Q · 2025-08-07T00:00:00.000Z [bullish] Risk: medium
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported total revenue of $40.0 million for the second quarter of 2025, a significant increase from $30.0 million
• PacBio Reports Director Changes and Executive Appointments — 8-K · 2025-06-06T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. (PacBio) filed an 8-K on June 6, 2025, reporting on several key events that occurred on June 4, 2025. These include the
• PacBio Files Proxy Materials — DEFA14A · 2025-05-20T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. (PACB) filed a Definitive Additional Materials (DEFA14A) on May 20, 2025. This filing relates to the company's proxy sta
• PacBio Files Q1 2025 10-Q — 10-Q · 2025-05-12T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. (PACB) filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational upd
• PACB Files 8-K on Operations and Financials — 8-K · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  On May 8, 2025, Pacific Biosciences of California, Inc. (PACB) filed an 8-K report. The filing primarily concerns the company's results of operations and financ
• PacBio Files DEF 14A: Executive Compensation Details — DEF 14A · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. (PACB) filed a DEF 14A on April 23, 2025, for the fiscal year ending December 31, 2024. The filing details executive com
• PacBio Files 8-K on Financials and Exit Costs — 8-K · 2025-04-09T00:00:00.000Z [neutral] Risk: medium
  On April 9, 2025, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report. The filing primarily concerns the company's financial condition and resu
• PacBio CFO Departs; New Directors Appointed — 8-K · 2025-03-27T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. (PacBio) announced on March 24, 2025, the departure of its Chief Financial Officer, Christian O. Knutson, effective Marc
• PacBio Files 2024 10-K, Details Financials — 10-K · 2025-03-17T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. (PACB) filed its 2024 10-K on March 17, 2025, reporting its financial performance for the fiscal year ending December 31
• PacBio Enters Material Definitive Agreement — 8-K · 2025-03-13T00:00:00.000Z [neutral] Risk: medium
  On March 7, 2025, Pacific Biosciences of California, Inc. (PacBio) entered into a material definitive agreement. This filing also indicates the creation of a di
• PacBio Files 8-K on Financials — 8-K · 2025-02-13T00:00:00.000Z [neutral] Risk: low
  On February 13, 2025, Pacific Biosciences of California, Inc. (PACB) filed an 8-K report. The filing primarily concerns the company's financial condition and re
• PacBio Files 8-K/A Amendment on Officer/Director Changes — 8-K/A · 2025-02-07T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on February 7, 2025, reporting changes effective January 24, 2025. The filing concerns the de
• PacBio Announces Director Changes and Compensatory Arrangements — 8-K · 2025-01-30T00:00:00.000Z [neutral] Risk: low
  On January 24, 2025, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report detailing the departure of Director Dr. Susan J. Molineaux and the app
• PacBio Files 8-K on Operations and Financials — 8-K · 2025-01-14T00:00:00.000Z [neutral] Risk: low
  On January 14, 2025, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report. The filing primarily concerns the company's results of operations and
• PacBio Files 8-K/A Amendment on Leadership Changes — 8-K/A · 2024-12-13T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on November 11, 2024, related to the departure of directors, election of directors, appointme
• PacBio Appoints New Chief Medical Officer — 8-K · 2024-12-06T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. (PacBio) announced on December 5, 2024, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer. Dr. Michaels
• SC 13G Filing — SC 13G · 2024-11-26T00:00:00.000Z [neutral]
• PacBio Files 8-K: Material Agreements, Financial Obligations, Equity Sales — 8-K · 2024-11-22T00:00:00.000Z [neutral] Risk: medium
  On November 21, 2024, Pacific Biosciences of California, Inc. (PacBio) filed an 8-K report detailing several significant events. These include entering into a m
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• PacBio Files Q3 2024 10-Q with Revenue Details — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. (PACB) filed its 10-Q for the period ending September 30, 2024. The company reported revenue for the third quarter of 20
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• PacBio Enters Material Definitive Agreement, Reports Equity Sales — 8-K · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  On November 7, 2024, Pacific Biosciences of California, Inc. (PacBio) entered into a material definitive agreement related to a direct financial obligation. The
• SC 13G/A Filing — SC 13G/A · 2024-11-04T00:00:00.000Z [neutral]
• PacBio Files Q2 2024 10-Q with Revenue Details — 10-Q · 2024-08-09T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. (PACB) filed its 10-Q for the period ending June 30, 2024. The company reported revenue for the second quarter of 2024 a
• PacBio Files 8-K/A Amendment on Exit Costs — 8-K/A · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on August 7, 2024, to its report originally filed on April 16, 2024. This amendment pertains
• PacBio Announces Board Changes and Officer Appointments — 8-K · 2024-06-20T00:00:00.000Z [neutral] Risk: medium
  On June 18, 2024, Pacific Biosciences of California, Inc. (PacBio) announced changes to its Board of Directors, including the election of new directors and the
• PacBio Files Additional Proxy Materials — DEFA14A · 2024-05-30T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. (PacBio) filed a Definitive Additional Materials (DEFA14A) on May 30, 2024. This filing relates to the company's proxy s
• PacBio Files Q1 2024 10-Q — 10-Q · 2024-05-09T00:00:00.000Z [neutral] Risk: medium
  Pacific Biosciences of California, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported revenue from product sales and services. Key f
• PacBio DEF 14A: Executive Compensation & Annual Meeting Details — DEF 14A · 2024-04-29T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. (PACB) filed its DEF 14A on April 29, 2024, detailing executive compensation and annual meeting matters for the fiscal y
• PacBio Files 8-K: Operations, Costs, and Financials — 8-K · 2024-04-16T00:00:00.000Z [neutral] Risk: medium
  On April 16, 2024, Pacific Biosciences of California, Inc. filed an 8-K report detailing financial results and other events. The filing includes information on
• PacBio Files 10-K, Details 2023 Performance — 10-K · 2024-02-28T00:00:00.000Z [neutral] Risk: medium
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filed its 10-K on February 28, 2024, for the fiscal year ending December 31, 2023. The company, a Large Accelerated File
• PacBio Files 8-K on Financial Results and Exhibits — 8-K · 2024-02-15T00:00:00.000Z [neutral] Risk: low
  Pacific Biosciences of California, Inc. filed an 8-K on February 15, 2024, to report on its results of operations and financial condition. The filing also indic
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Nikko Asset Management Amends PacBio Stake as of Dec 31, 2023 — SC 13G/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  Nikko Asset Management Americas, Inc. filed an amended SC 13G/A on February 12, 2024, indicating their ownership of Pacific Biosciences of California, Inc. comm
• Jackson Square Partners Amends PACB Stake as of Dec 31, 2023 — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  Jackson Square Partners, LLC filed an amended SC 13G/A on February 9, 2024, indicating their ownership of Pacific Biosciences of California Inc. (PACB) common s
• Sumitomo Mitsui Trust Amends PacBio Stake Disclosure — SC 13G/A · 2024-02-05T00:00:00.000Z [neutral]
  Sumitomo Mitsui Trust Holdings, Inc. filed an amended Schedule 13G/A on February 5, 2024, indicating a change in their beneficial ownership of Pacific Bioscienc
• ARK Investment Management Cuts PACB Stake to 4.3% — SC 13G/A · 2024-01-29T00:00:00.000Z [bearish]
  ARK Investment Management LLC, led by Cathie Wood, filed an amendment to its SC 13G, indicating a change in its beneficial ownership of Pacific Biosciences of C
• BlackRock Amends PacBio Stake, Signals Passive Investment Update — SC 13G/A · 2024-01-24T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating its ownership of Common Stock in PACIFIC BIOSCIENCES OF CALIFORNIA, INC. as of De
• Vanguard Discloses 6.09% Stake in Pacific Biosciences — SC 13G/A · 2024-01-10T00:00:00.000Z [neutral]
  The Vanguard Group, a major investment firm, filed an amended Schedule 13G/A on January 10, 2024, indicating its ownership of 16,063,056 shares of Common Stock
• PACB Files 8-K on Financial Condition, NASDAQ Listing Confirmed — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Pacific Biosciences of California, Inc. (PACB) filed an 8-K on January 8, 2024, to report on its financial condition and other events. This filing indicates tha